Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]
Gynecol Oncol
.
2023 Feb:169:173.
doi: 10.1016/j.ygyno.2022.11.010.
Epub 2022 Nov 28.
Authors
Rodney P Rocconi
1
,
Bradley J Monk
2
,
Adam Walter
3
,
Thomas J Herzog
4
,
Evanthia Galanis
5
,
Luisa Manning
6
,
Ernest Bognar
6
,
Gladice Wallraven
6
,
Laura Stanbery
6
,
Phylicia Aaron
6
,
Neil Senzer
6
,
Robert L Coleman
7
,
John Nemunaitis
8
Affiliations
1
University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States of America.
2
Arizona Oncology, Phoenix, AZ, United States of America.
3
ProMedica, Toledo, OH, United States of America.
4
University of Cincinnati Cancer Center, Cincinnati, OH, United States of America.
5
Mayo Clinic, Rochester, MN, United States of America.
6
Gradalis, Inc., Carrollton, TX, United States of America.
7
US Oncology Research, The Woodlands, TX, United States of America.
8
Gradalis, Inc., Carrollton, TX, United States of America. Electronic address: Johnnemunaitis@gmail.com.
PMID:
36456375
DOI:
10.1016/j.ygyno.2022.11.010
No abstract available
Publication types
Published Erratum